Measles, mumps and rubella vaccination

MMR and MMRV Vaccines

• MMR (measles, mumps, rubella) and MMRV (measles, mumps, rubella, varicella) vaccines contain live, attenuated strains of measles, mumps, rubella, and varicella viruses
• administered intramuscularly into the upper arm or anterolateral thigh
• deep subcutaneous injections or preferred subcutaneous routes are used for patients with bleeding disorders to minimize hematoma risk
• the routine UK childhood immunisation schedule incorporates the combination MMRV vaccine alongside the traditional MMR vaccine, moving the second routine dose to 18 months of age

Routine UK Schedule and Eligibility (1)

• traditional MMR history: introduced in the UK in 1988 with a target of 90% uptake in 1 to 2 year olds; a routine second dose was added in 1996
• updated routine schedule (born on or after 1 January 2025):
  • dose 1: MMRV at 12 months
  • dose 2: MMRV at 18 months
• transition schedules for older cohorts (born prior to 1 January 2025):
  • born 1 July 2024 – 31 December 2024: MMR at 12 months, MMRV at 18 months, and MMRV at 3 years 4 months
  • born 1 September 2022 – 30 June 2024: MMR at 12 months and MMRV at 3 years 4 months
• purpose of the second dose: primary aim is not to act as a booster, but to protect the small proportion of individuals who failed to seroconvert after the first dose
• timing flexibility: second MMR or MMRV dose can be administered at any time after the first, provided a minimum interval of 4 weeks (or 3 months if given under 18 months of age) has elapsed

Efficacy

• single-dose efficacy:
  • measles: protects ~90% of children
  • rubella: confers around 95–100% protection
  • mumps: confers between 61% and 91% protection
  • varicella: single-dose varicella-containing vaccine confers high-level protection against severe varicella infection
• two-dose requirement: two doses of MMR- or MMRV-containing vaccine are required to produce long-term, satisfactory population protection against measles, mumps, rubella, and varicella

Safety Myths and Contraindications

• no autism or IBD link: robust evidence confirms no causal link between MMR/MMRV vaccines and autism or Crohn's disease
• contraindications: severe immunosuppression, confirmed systemic anaphylaxis to a prior dose or vaccine components (neomycin, gelatin), and pregnancy (precautionary measure)

Co-administration with Other Vaccines and Tuberculin Testing

• concurrent administration: MMR and MMRV can be given at the same time as other routine childhood vaccines (e.g., DTaP/IPV/Hib/HepB, MenB, PCV)
  • separate sites: give in a separate site, preferably a different limb; if administered in the same limb, separate by at least 2.5 cm
• co-administration with other live vaccines:
  • MMR/MMRV should ideally be administered on the same day as other live vaccines (e.g., BCG)
  • if live vaccines are given on the same day, each vaccine virus replicates independently to elicit an appropriate immune response
  • if not given simultaneously, natural interferon production from the first live vaccine may inhibit viral replication of the second; therefore, observe a 4-week interval between non-simultaneous live vaccine doses
• tuberculin testing (Mantoux test): leave a 4-week interval between administering MMR/MMRV and conducting tuberculin testing, as the attenuation of delayed-type hypersensitivity by the measles virus component can cause a false-negative result

Special Clinical Notes and Allergies

• pregnancy and live vaccines: long-standing guidance advises avoiding live vaccines during pregnancy or within 1 month prior to conception due to theoretical viral transmission risks; however, extensive UK and international surveillance data confirm a complete lack of evidence of risk of harm or congenital abnormalities if MMR or MMRV is inadvertently administered in pregnancy (2)
  • non-indication for termination: inadvertent administration during pregnancy is not a clinical indication for termination, and patients should be immediately reassured
• egg allergy: children with egg allergy can safely receive MMR or MMRV vaccines in primary care
  • vaccine viral strains are not cultured on egg tissues in a manner that yields clinically significant egg protein
  • anaphylactic reactions are typically associated with non-egg components such as gelatin or neomycin
  • in rare cases of confirmed systemic anaphylaxis to egg-containing foods, consult pediatric specialists regarding supervised administration
• gelatin-free options: Priorix and Priorix-Tetra are gelatin-free alternatives available for individuals who avoid porcine gelatine
• prescribing resources: check the latest UKHSA Green Book (Chapters 11, 21, and 23) and individual Summary of Product Characteristics (SmPC) prior to administration

Reference

1. UK Health Security Agency. Immunisation against infectious disease (The Green Book). Chapter 21: Measles. Guidance document. Updated October 2026.
2. UK Health Security Agency (UKHSA). The Safety of MMR and MMRV (Measles, Mumps, Rubella and Varicella) Vaccine when given in Pregnancy: Advice for Healthcare Professionals and Pregnant Women. Guidance document. Updated October 8, 2026.